| First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer BJ Solomon, T Mok, DW Kim, YL Wu, K Nakagawa, T Mekhail, E Felip, ... New England Journal of Medicine 371 (23), 2167-2177, 2014 | 3600 | 2014 |
| Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study CS Fuchs, J Marshall, E Mitchell, R Wierzbicki, V Ganju, M Jeffery, ... Journal of Clinical Oncology 25 (30), 4779-4786, 2007 | 1143 | 2007 |
| Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant … TM Beer, ED Kwon, CG Drake, K Fizazi, C Logothetis, G Gravis, V Ganju, ... Journal of Clinical Oncology 35 (1), 40-47, 2017 | 732 | 2017 |
| Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III … NC Tebbutt, K Wilson, VJ Gebski, MM Cummins, D Zannino, ... | 506 | 2010 |
| Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised … C Eng, TW Kim, J Bendell, G Argilés, NC Tebbutt, M Di Bartolomeo, ... The lancet oncology 20 (6), 849-861, 2019 | 456 | 2019 |
| SIRFLOX: randomized phase III trial comparing first-line mFOLFOX6 (plus or minus bevacizumab) versus mFOLFOX6 (plus or minus bevacizumab) plus selective internal radiation … GA Van Hazel, V Heinemann, NK Sharma, MPN Findlay, J Ricke, ... Journal of Clinical Oncology 34 (15), 1723-1731, 2016 | 401 | 2016 |
| First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE … HS Wasan, P Gibbs, NK Sharma, J Taieb, V Heinemann, J Ricke, ... The Lancet Oncology 18 (9), 1159-1171, 2017 | 381 | 2017 |
| Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 … IE Krop, IA Mayer, V Ganju, M Dickler, S Johnston, S Morales, DA Yardley, ... The lancet oncology 17 (6), 811-821, 2016 | 294 | 2016 |
| Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label … SA Hurvitz, R Hegg, WP Chung, SA Im, W Jacot, V Ganju, JWY Chiu, B Xu, ... The Lancet 401 (10371), 105-117, 2023 | 277 | 2023 |
| Cancer stem cells in lung cancer: Evidence and controversies M Alamgeer, CD Peacock, W Matsui, V Ganju, DN Watkins Respirology 18 (5), 757-764, 2013 | 176 | 2013 |
| The evolution of therapies in non-small cell lung cancer V Boolell, M Alamgeer, DN Watkins, V Ganju Cancers 7 (3), 1815-1846, 2015 | 155 | 2015 |
| Prognostic Factors of Survival in a Randomized Phase III Trial (MPACT) of Weekly nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone in Patients With … J Tabernero, EG Chiorean, JR Infante, SR Hingorani, V Ganju, C Weekes, ... The oncologist 20 (2), 143-150, 2015 | 148 | 2015 |
| Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international … TJ Price, D Zannino, K Wilson, RJ Simes, J Cassidy, GA Van Hazel, ... Annals of oncology 23 (6), 1531-1536, 2012 | 142 | 2012 |
| Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial NC Tebbutt, MM Cummins, T Sourjina, A Strickland, G Van Hazel, ... British journal of cancer 102 (3), 475-481, 2010 | 134 | 2010 |
| A randomized phase 3 trial comparing pemetrexed/carboplatin and docetaxel/carboplatin as first-line treatment for advanced, nonsquamous non-small cell lung cancer J Rodrigues-Pereira, JH Kim, M Magallanes, DH Lee, J Wang, V Ganju, ... Journal of Thoracic Oncology 6 (11), 1907-1914, 2011 | 112 | 2011 |
| Novel therapeutic targets in non-small cell lung cancer M Alamgeer, V Ganju, DN Watkins Current opinion in pharmacology 13 (3), 394-401, 2013 | 110 | 2013 |
| Prognostic gene expression signature for high-grade serous ovarian cancer J Millstein, T Budden, EL Goode, MS Anglesio, A Talhouk, ... Annals of oncology 31 (9), 1240-1250, 2020 | 108 | 2020 |
| Region‐specific loss of heterozygosity on chromosome 19 is related to the morphologic type of human glioma SR Ritland, V Ganju, DRB Jenkins Genes, Chromosomes and Cancer 12 (4), 277-282, 1995 | 107 | 1995 |
| Prognostic factors in gliomas. A multivariate analysis of clinical, pathologic, flow cytometric, cytogenetic, and molecular markers V Ganju, RB Jenkins, JR O'Fallon, BW Scheithauer, DT Ransom, ... Cancer 74 (3), 920-927, 1994 | 105 | 1994 |
| Current status of adjuvant chemotherapy for colorectal cancer: can molecular markers play a role in predicting prognosis? MJ O'Connell, DJ Schaid, V Ganju, J Cunningham, JS Kovach, ... Cancer 70 (S4), 1732-1739, 1992 | 99 | 1992 |
